It operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 37% a year on average.
Sales run at $85K a year. A small number, but proof the product has real buyers.
A loss of $1.2M against $85K in annual sales.
The stock sits at $0.0027. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, UNVC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: UNVC is a high-risk stock — not yet profitable, and its future rides on its product catching on.